Background: Genotype 3 increases fibrosis in chronic hepatitis C (CHC). Aim: To evaluate the effect of the hepatitis C virus (HCV) genotype on prevalence and severity of liver disease in CHC. Materials and methods: Nine hundred and forty-nine individuals with positive anti-HCV from June 2016 to May 2017 were enrolled in the study. We compared biochemical and hematological parameters, HCV RNA load, transient elastography, and ultrasound, in genotype 3 and nongenotype 3 patients. Cirrhosis was diagnosed in patients with liver stiffness measurement (LSM) ≥13 kPa. Results: Out of 835 CHC patients, overall, genotype 3 had higher LSM (11.3 vs 7.62, p = 0.01), higher aspartate aminotransferase (AST) (88.4 vs 68.6, p = 0.02), and low platelets (228.4 vs 261, p = 0.03) with higher prevalence of cirrhosis (115/415 vs 25/245, p = 0.01) than nongenotype 3. However, decompensation rates were not significantly different between two groups (32/115 vs 7/25, p = 0.98). The subgroup analysis revealed that cirrhotic genotype 3 had advanced age (50 vs 35, p < 0.01), male predominance, and higher AST (74.4 vs 57, p = 0.01) as compared to noncirrhotic genotype 3 patients. On multivariate analysis, age and AST values were higher in cirrhotic than noncirrhotic genotype 3 patients. Conclusion: Genotype 3 patients have higher prevalence of cirrhosis and fibrosis compared to nongenotype 3 patients; however, decompensation was not different between two groups.
Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006;44(1 Suppl):S19–S24. DOI: 10.1016/j.jhep.2005.11.009.
Rüeger S, Bochud PY, Dufour JF, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 2015;64(10):1605–1615. DOI: 10.1136/gutjnl-2014-306997.
Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134(6):1699–1714. DOI: 10.1053/j.gastro.2008.02.069.
Raimondi S, Bruno S, Mondelli MU, et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009;50(6):1142–1154. DOI: 10.1016/j.jhep.2009.01.019.
Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J Viral Hepat 2011;18(11):745–759. DOI: 10.1111/j.1365-2893.2011.01481.x.
Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60(1):98–105. DOI: 10.1002/hep.27095.
Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int 2011;5(2):625–634. DOI: 10.1007/s12072-010-9240-0.
Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128(2):343–350. DOI: 10.1053/j.gastro.2004.11.018.
European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63(1):237–264. DOI: 10.1016/j.jhep.2015.04.006.
Colli A, Fraquelli M, Andreoletti M, et al. Severe liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 cases. Radiology 2003;227(1):89–94. DOI: 10.1148/radiol.2272020193.
Yeom SK, Lee CH, Cha SH, et al. Prediction of liver cirrhosis, using diagnostic imaging tools. World J Hepatol 2015;7(17):2069–2079. DOI: 10.4254/wjh.v7.i17.2069.
Lehmann M, Meyer MF, Monazahian M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004;73(3):387–391. DOI: 10.1002/jmv.20103.
Mitchell AM, Stone AE, Cheng L, et al. Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver. mBio 2015;6(2):e02510. DOI: 10.1128/mBio.02510-14.
Negro F. Hepatitis C virus-induced steatosis: an overview. Dig Dis 2010;28(1):294–299. DOI: 10.1159/000282105.
Ryan MC, Desmond PV, Slavin JL, et al. Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. J Viral Hepat 2011;18(1):53–60. DOI: 10.1111/j.1365-2893.2010.01283.x.
Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38(1):75–85. DOI: 10.1053/jhep.2003.50267.
Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36(5):1266–1272. DOI: 10.1053/jhep.2002.36370.
Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33(1):106–115. DOI: 10.1016/S0168-8278(00)80166-X.
Bochud P-Y, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51(4):655–666. DOI: 10.1016/j.jhep.2009.05.016.
De Nicola S, Aghemo A, Rumi MG, et al. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009;51(5):964–966. DOI: 10.1016/j.jhep.2009.08.001.